Von Willebrand Factor Regulation in Patients with Acute and Chronic Cerebrovascular Disease: A Pilot, Case–Control Study

Peter Kraft1,4, Christiane Drechsler2, Ignaz Gunreben1, Bernhard Nieswandt2, Guido Stoll1, Peter Ulrich Heuschmann3,4, Christoph Kleinschnitz1*

1 Department of Neurology, University Hospital Würzburg, Würzburg, Germany, 2 Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany, 3 The Clinical Trial Center, University Hospital Würzburg, Würzburg, Germany, 4 Institute of Clinical Epidemiology and Biometry, Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, 5 Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany

Abstract

Background and Purpose: In animal models, von Willebrand factor (VWF) is involved in thrombus formation and propagation of ischemic stroke. However, the pathophysiological relevance of this molecule in humans, and its potential use as a biomarker for the risk and severity of ischemic stroke remains unclear. This study had two aims: to identify predictors of altered VWF levels and to examine whether VWF levels differ between acute cerebrovascular events and chronic cerebrovascular disease (CCD).

Methods: A case–control study was undertaken between 2010 and 2013 at our University clinic. In total, 116 patients with acute ischemic stroke (AIS) or transitory ischemic attack (TIA), 117 patients with CCD, and 104 healthy volunteers (HV) were included. Blood was taken at days 0, 1, and 3 in patients with AIS or TIA, and once in CCD patients and HV. VWF serum levels were measured and correlated with demographic and clinical parameters by multivariate linear regression and ANOVA.

Results: Patients with CCD (158 ± 46%) had significantly higher VWF levels than HV (113 ± 36%, P < 0.001), but lower levels than AIS/TIA patients (200 ± 95%, P < 0.001). Age, sex, and stroke severity influenced VWF levels (P < 0.05).

Conclusions: VWF levels differed across disease subtypes and patient characteristics. Our study confirms increased VWF levels as a risk factor for cerebrovascular disease and, moreover, suggests that it may represent a potential biomarker for stroke severity, warranting further investigation.

Background

Plasmatic coagulation and platelets are critically involved in lesion development after ischemic stroke (IS) [1,2]; however, their specific roles and their interplay with endothelial cells or other resident brain cells long remained elusive. Recently, the development of transgenic mouse models and specific antibodies has enabled the discovery of distinct pathways in pathological thrombus formation in animal models of IS [2,3]. Von Willebrand factor (VWF) plays a key pathophysiologic role in arterial thrombus formation in the brain and heart [4,5]. VWF is a large, multimeric glycoprotein that is exclusively synthesized in endothelial cells and megakaryocytes and circulates as multimers of varying size (up to 20,000 kDa). A disintegrin and metalloprotease with thrombospondin type 1 repeats 13 (ADAMTS13) digests ultralarge VWF into smaller and less reactive molecules [4]. VWF mediates loose adhesion of platelets to the vascular wall and therefore, the earliest step of thrombus formation through binding to glycoprotein (Gp)Ib expressed on platelets [2,6].

Research to date has shown that in vivo blockade of the GpIb–VWF axis resulted in the elimination of arterial thrombus formation in primates [7], restored vessel patency by dissolving platelet aggregates [8], and led to significantly reduced infarct volumes and better functional outcome in rodent stroke models [4–6] and larger animals [9]. Furthermore, targeting GpIb and its major ligand VWF has provided beneficial effects in IS models without a concomitant increase in bleeding complications, which led to the unique and intriguing concept of a potential “bleeding–free” antithrombotic approach [2]. Thus, targeting VWF-mediated platelet adhesion and activation is now considered as a potential target for stroke prevention and acute stroke treatment. However,
a conservative view is warranted given that attempts to translate the findings with this approach from animal stroke studies to humans has yielded disappointing results [10].

Despite increasing evidence of a causal association between VWF levels and acute stroke risk in humans [11,12] many questions remain unanswered. For instance, the processes involved in the regulation of VWF expression during ischemic stroke and the specific contribution of VWF to the preceding pathophysiologic events await clarification. Also, the relationship of VWF levels to other parameters, such as genetic polymorphisms [13] and demographic features [14], is not well understood. Additionally, only limited data exist on the regulation of VWF in patients with chronic cerebrovascular disease (CCD) [15–17].

The aim of the study was to identify demographic and clinical predictors of VWF serum levels and to evaluate whether VWF levels differ between acute cerebrovascular events and chronic cerebrovascular disease (CCD).

**Methods**

**Data Collection**

For addressing these objectives, a case-control study was performed. As cases, patients with acute (acute ischemic stroke

### Table 1. Baseline characteristics of acute ischemic stroke (AIS)/transitory ischemic attack (TIA) patients.

| Characteristic                             | Value (n = 116) |
|--------------------------------------------|----------------|
| Age, years                                 | 70±12          |
| Sex, n (%)                                 |                |
| Male                                       | 62 (53)        |
| Female                                     | 54 (47)        |
| Modality, n (%)                            |                |
| AIS                                         | 67 (58)        |
| TIA                                         | 49 (42)        |
| TOAST criteria, n (%)                      |                |
| Cardioembolism                             | 70 (60)        |
| Large-artery atherosclerosis               | 4 (3)          |
| Small-vessel occlusion                     | 12 (10)        |
| Other determined or undetermined etiology  | 30 (26)        |
| Thrombolysis, n (%)                        | 34 (29)        |
| Comorbidities, n (%)                       |                |
| Hypertension                               | 105 (92)       |
| Diabetes mellitus                          | 41 (35)        |
| Hyperlipidemia                             | 80 (69)        |
| Renal failure                              | 10 (9)         |
| Atrial fibrillation                        | 37 (32)        |
| Persistent foramen ovale                   | 28 (24)        |
| Heart failure                              | 5 (4)          |
| Coronary artery disease                    | 8 (7)          |
| Family history of stroke                   | 11 (10)        |
| Smoking, n (%)                             | 18 (16)        |
| Platelet inhibitor before blood withdrawal, n (%) | 87 (75)    |
| Anticoagulation before blood withdrawal, n (%) | 8 (7)       |
| Lipid-lowering drug before blood withdrawal, n (%) | 36 (31)   |
| National Institutes of Health Stroke Scale at admission | 4.8±6.0 |
| Barthel Index at admission                 | 74±30          |
| Body mass index, kg/m²                     | 27±5           |
| HbA1c, mmol/mol hemoglobin                 | 46±13          |
| Lipid profile, mmol/L                      |                |
| Total cholesterol                          | 202±52         |
| Low-density lipoprotein                    | 121±45         |
| High-density lipoprotein                   | 51±15          |
| Triglycerides                              | 157±153        |
| Duration between symptom onset and blood withdrawal, h | 14±7         |

HbA1c, glycated hemoglobin; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
doi:10.1371/journal.pone.0099851.t001
Blood Collection and Measurements

Blood was collected on day 0, 1, and 3 in the patients with acute cerebrovascular disease, and once in CCD patients and HV between 08.00 and 12.00 hours from an antecubital vein using a 21-gauge butterfly needle. Pre-analytic preparations for blood collection followed a specific standard operating procedure. Only non-hemolyzed blood samples were analysed. VWF, differential hematology parameters, and C-reactive protein (CRP) were analysed at the Division of Laboratory Medicine of the University Hospital Würzburg.

Figure 1. von Willebrand factor (VWF) levels in acute ischemic stroke (AIS)/transitory ischemic attack (TIA), chronic cerebrovascular disease (CCD), and healthy volunteers (HV). The VWF levels are depicted in box-and-whisker plots indicating the first and third quartiles as well as the 1.5 interquartile range (IQR, Tukey plot). Outliers outside 1.5 IQR are visualized by single dots. VWF levels showed significant differences between the three groups. Analysis of variance with Bonferroni post hoc test, ***, P < 0.001, d0 = day 0.

doi:10.1371/journal.pone.0099851.g001

Statistical Analysis

Continuous variables are expressed as mean with standard deviation or median with interquartile range, as appropriate. Categorical variables are expressed as percentages. The association between VWF concentrations and a range of demographic and clinical characteristics was explored: age, sex, neurological scales, disease modality (TIA or AIS), TOAST criteria, duration between symptom onset and blood withdrawal, NIHSS, Barthel Index, treatment modality (intravenous thrombolyis or not), and intake of platelet inhibitors in the days before blood withdrawal. P values for comparisons across groups of clinical and demographic characteristics were derived from analysis of variance (ANOVA), and the chi-square test, as appropriate. In order to identify potential predictors of VWF levels, a linear regression model was used that included all variables without co-linearity in a multivariate model adjusting for age and sex. Using this model, coefficients and the corresponding 95% confidence intervals (CIs) were estimated. VWF biomarker levels were compared between the different patients groups (AIS/TIA in-patients, CCD out-patients, or HV). Distribution was analyzed using the Kolmogorov–Smirnov test. Levels of VWF were assumed to take a normal distribution and were compared using ANOVA with a Bonferroni post-hoc test and additionally adjusted for age and sex. All reported P values are two-sided and a P value < 0.05 was considered statistically significant. Analyses were performed using SPSS Version 21 and SAS software version 9.1 (SAS Institute Inc., Cary, NC).

Ethics

Informed written consent was obtained from all participants. The study protocol was approved by the ethics committee of the medical faculty of the University of Würzburg, Germany (reference number 65/2010). Study participation had no influence on treatment and patient care.

Results

Descriptive Analysis of the Patients with an Acute Cerebrovascular Event

A total of 116 patients with AIS/TIA were included in this study. The mean age of these patients was 70 ± 12 years; 53% of whom were male. The baseline clinical severity measured with NIHSS and Barthel Index was 4.8 ± 6.0 and 74 ± 30, respectively. More than half of the patients had an AIS (58%). A detailed descriptive analysis of the characteristics of the patients with acute cerebrovascular event is given in Table 1.

Comparison of VWF Levels in AIS/TIA Patients, CCD Patients, and HV

VWF levels by patient subtype with acute cerebrovascular events (AIS or TIA), or chronic cerebrovascular disorders (CCD), were compared with the levels of HV. VWF levels showed significant differences between the three groups (AIS/TIA: 200 ± 95%; CCD: 158 ± 46%; HV: 113 ± 36%) (Figure 1). Both patient subtypes had significantly higher levels than HV, AIS and TIA patients even higher than CCD patients (all P < 0.001). After adjustment for age and sex, highly significant results remained (P < 0.001) (data not shown).
The potential relationship between VWF levels and standard laboratory parameters such as CRP or blood count was evaluated. VWF levels were significantly correlated with CRP ($r = 0.30$, $P = 0.001$) and different leukocyte subsets (leukocyte count: $r = 0.29$, $P = 0.002$; neutrophil count: $r = 0.36$, $P < 0.001$; lymphocyte count: $r = -0.28$, $P = 0.002$; monocyte count: $r = 0.20$, $P = 0.03$) (data not shown).

The association between VWF levels and key demographic and clinical characteristics was assessed in a univariate analysis (Table 2). Age ($P = 0.001$), disease modality (TIA vs. AIS) ($P = 0.01$), and clinical severity (NIHSS: $P = 0.001$; Barthel Index: $P < 0.001$) showed a significant association with serum VWF levels. VWF levels increased with patient age and clinical severity, while AIS patients had higher VWF levels than TIA patients.

A multivariate analysis of all variables was performed using a linear regression model (Table 3). Three parameters: NIHSS $> 15$ points, intake of platelet inhibitors before blood withdrawal, and CRP at admission, were identified as independent predictors of VWF levels. The time point of blood withdrawal (days 0, 1 and 3) did not influence VWF levels ($P = 0.99$) (data not shown).
Discussion

This study shows that VWF serum levels are significantly increased in both acute and chronic cerebrovascular disorders compared with healthy persons. Furthermore, we identified important demographic and clinical predictors of VWF levels in patients with acute IS or transitory ischemic attack.

It is known that VWF is a risk factor for coronary heart disease [21–23]. Despite a few studies that could not find an association between VWF levels and stroke risk or increased coagulability [22,23], the vast majority of prospective studies point towards high VWF levels as risk factor also for AIS [12,24–28]. Our findings support this hypothesis by showing that VWF levels are higher in patients with an acute cerebrovascular event or CCD than in healthy individuals. Importantly, stroke severity (NIHSS >15 points), CRP levels at admission, and the intake of platelet inhibitors in the days before blood withdrawal each independently predicted VWF levels.

Previous case-control studies demonstrated increased VWF levels in patients with IS [11,29–31]. While Hanson and co-workers described that VWF levels differed between etiologic subtypes of IS, we found no such association [29]. Our finding of an association of CRP and VWF levels in the acute phase after IS highlights the role of VWF as an acute-phase reactant associated with inflammation [32] and, in particular, with thrombo-inflammation [4,33,34]. The term “thrombo-inflammation” describes the interaction of thrombotic (e.g., coagulation factors, platelets) and inflammatory (e.g., immune cells) circuits operating at the ischemic neurovascular unit and has recently been identified as key mechanism of stroke occurrence and propagation at least in rodents [33,34].

Elevated levels of VWF in patients with chronic cerebrovascular disease compared with healthy controls presented herein is similar to the findings of a previous study, which showed that subjects with carotid plaques have elevated VWF levels [35]. In addition, a recent report shows that atherosclerotic geometries exacerbate pathological thrombus formation post-stenosis in a VWF-dependent manner [36]. However, findings from another investigation suggest that the additional explanatory power of VWF (on top of the traditional risk factors, such as hypertension and diabetes) is comparatively low in patients with carotid atherosclerosis [37].

Growing evidence indicates that demographic and clinical parameters as well as therapeutic interventions can influence VWF levels [16,17], but the relevance of these variables on VWF regulation in different disease settings is unclear. Our findings, and those of other researchers, underline the complexity of associations with VWF levels. On the one hand, a high VWF level at admission is indicated as a marker of severe IS; on the other hand, VWF level is influenced by a variety of other variables (e.g., ABO blood group [38–41], existence and composition of carotid plaques [13,16]) which complicates its interpretation. Only recently, it has been shown that extracellular sodium levels within the high physiological range can raise VWF levels thereby increasing the risk of pathological thrombosis [42].

Our findings raise important considerations for clinical practice. It may be hypothesized that VWF level could represent a potential biomarker of stroke risk and stroke severity. Yet, the proactive screening of VWF levels on a regular basis to assess the risk of thromboembolic disease in individual patients has still not been recommended by medical societies [4]. This may be due to the lack of standardized test systems [4], or the confounding of measurements by the current lack of understanding of factors that influence VWF levels [13,14] – which would impede the interpretation of findings and the prediction of the corresponding cerebrovascular risk.

In addition, VWF levels could perhaps provide a means to screen patients for specific treatment approaches. In various stroke models, blocking VWF by monoclonal antibodies has been shown to prevent or ameliorate pathological thrombosis [42].

Table 3. Predictors of von Willebrand factor levels in acute ischemic stroke (AIS)/transitory ischemic attack (TIA) patients by multivariate analysis.

| Predictor                          | Coefficient | 95% confidence interval       | P value |
|-----------------------------------|-------------|-------------------------------|---------|
| Sex                               |             |                               |         |
| Male                              | Reference   |                               |         |
| Female Age, years                  | 4.12±15.75  | −27.13 to 35.37               | 0.79    |
| <55                               | Reference   |                               |         |
| 55–64                             | 37.28±27.04 | −16.35 to 90.92               | 0.17    |
| 65–74                             | 24.43±25.22 | −25.62 to 74.47               | 0.34    |
| 75–84                             | 39.70±26.68 | −13.23 to 92.64               | 0.14    |
| >84                               | 37.83±33.84 | −29.30 to 104.97              | 0.27    |
| Disease modality                  |             |                               |         |
| National Institutes of Health Stroke Scale |           |                               |         |
| 0–4                               | Reference   |                               |         |
| 5–9                               | 11.20±23.52 | −35.47 to 57.86               | 0.64    |
| 10–15                             | 36.75±27.77 | −18.35 to 91.86               | 0.19    |
| >15                               | 71.13±32.47 | 6.72 to 135.55                | 0.03    |
| Thrombolysis                      | −0.68±20.35 | −41.06 to 39.69               | 0.97    |
| Platelet inhibitor before blood taking | −41.09±16.66 | −74.13 to −8.05              | 0.02    |
| C-reactive protein at admission, mg/dl | 8.91±2.25     | 4.44 to 13.37                | <0.001  |
| Neutrophils at admission, n*1000/μl | 1.03±3.85     | −6.61 to 8.67                | 0.79    |

doi:10.1371/journal.pone.0099851.t003
to provide an impressive protective effect [5,9]. Assuming that patients with high VWF levels would benefit most from such a potential future pharmacological anti-VWF therapy, it could be important to identify those patients. Based on our results, patients with severe IS without previous intake of platelet inhibitors show the highest levels of VWF and could possibly be the target subgroup most suited to a targeted anti-VWF therapy. Of course, pharmacological targeting of VWF presents many challenges, and the highest levels of VWF and could possibly be the patient with severe IS without previous intake of platelet inhibitors show important to identify those patients. Based on our results, patients with high VWF levels would benefit most from such a potential future pharmacological anti-VWF therapy, it could be emphasized that this study describes the degree and significance of associations between VWF levels and demographic/clinical parameters, but does not assign causality. To overcome this limitation, prospective clinical trials should follow this case–control study. Furthermore, for ethical reasons, we could not recruit patients who were unable to give informed consent. Thus, patients with very large strokes and/or aphasia might be under-represented in our study. Further limitations include the relatively high proportion of TIA patients (42%) for which a non-vascular origin of symptoms cannot be entirely excluded, and treatment with anticoagulants in 7% of AIS/TIA patients which might interfere with the regulation of VWF levels.

Conclusion

In summary, we have demonstrated in this pilot study that an important potential biomarker and promising target for future therapeutic approaches, VWF, is differentially regulated in patients with acute and chronic cerebrovascular diseases. The ability to distinguish patient subtypes, or those at risk of an event, on the basis of VWF levels is a tempting approach that may enable better diagnosis or more targeted therapy in the future. In addition, this study adds to our knowledge of the factors that can influence VWF levels in a given patient. Nevertheless, prospective clinical trials are necessary to reproduce these results and to overcome the limitations that accompany retrospective study designs.

Acknowledgments

We thank Melanie Glaser, Andrea Sauer and Daniela Urlaub for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: PK CK. Performed the experiments: PK IG. Analyzed the data: PK CD PUH. Contributed to the writing of the manuscript: PK CD BN GS PUH CK.

References

1. Stegner D, Nieswandt B (2011) Platelet receptor signaling in thrombus formation. J Mol Med (Berl) 89: 109–121.
2. Kraft P, De Meyer SF, Kleinschnitz C (2012) Next-generation antithrombotics in ischemic stroke: preclinical perspective on ‘bleeding-free antithrombosis’. J Cereb Blood Perf Metab 32: 1831–1840.
3. Stoll G, Kleinschnitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112: 3555–3562.
4. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C (2012) von Willebrand factor: an emerging target in stroke therapy. Stroke 43: 599–606.
5. Kleinschnitz C, De Meyer SF, Schwarz T, Austmat M, Vanhoorelbeke K, et al. (2009) Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 113: 3600–3603.
6. Kleinschnitz C, Pozgajova J, Pham M, Benduzs M, Nieswandt B, et al. (2007) Targeting platelets in acute experimental stroke: impact of glycophorin Ib, VI, and Ib/IX/IXa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 115: 2323–2330.
7. Wu D, Vanhoorelbeke K, Gausenbergh N, Meiring M, Depaepeere H, et al. (2002) Inhibition of the von Willebrand (VWF): collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 99: 3625–3628.
8. Le Betho A, Gauberti M, Martinez de Lazarrondo S, Montagne A, lenmarcand E, et al. (2014) Gplinb-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood In press.
9. Moni S, Tantucci M, Van Roy M, Ulrichs H, Ricci G, et al. (2013) Reperfusion of cerebral artery thrombus by the GpIb-VWF blockade with the Nanobody ALX-0011 reduces brain infarct size in guinea pigs. Blood 121: 5088–5097.
10. Kleinschnitz C, Vanhoorelbeke K, Donnan GA, Horsley LL, van der Worp BH, et al. (2006) 0,026 experimental treatments in acute stroke. Ann Neurol 59: 467–477.
11. Bouwers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, et al. (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37: 2677–2682.
12. Wieberdnk RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, et al. (2012) Deficiency of von Willebrand factor protects mice from ischemic stroke. J Cereb Blood Perf Metab 32: 1831–1840.
13. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, et al. (2014) GpIb-endothelial markers are associated with thrombolysis resistance in acute stroke patients. Eur J Neuroil 21: 643–647.
14. Gauberti M, Martinez de Lazarrondo S, Orset C, Viven G (2014) Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates. J Thromb Haemost 12: 409–414.
15. Rodlan V, Marín F, García-Herola A, Lip GYH (2005) Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 116: 321–325.
16. Utsch CM, Sanz M, Huisse MG, Ajzenberg N, et al. (2014) Endothelial markers are associated with thrombosis resistance in acute stroke patients. Eur J Neuroil 21: 643–647.
17. Haufe D, Lachesre J, Meseger E, Huisse MG, Ajzenberg N, et al. (2014) Endothelial markers are associated with thrombosis resistance in acute stroke patients. Eur J Neuroil 21: 643–647.
18. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) A new methodological approach to assessment of clinical states after acute ischemic stroke: the TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.
19. Muir KW, Weir CJ, Murray GD, Povey C, Lees KR (1996) Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 27: 1817–1820.
20. Granger CV, Desio LS, Peters NC, Sherwood CC, Barrett JE (1979) Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil 60: 14–17.
21. Fischer CM (2006) Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 4: 1186–1193.
22. Faille D, Lachesre J, Meseger E, Huisse MG, Ajzenberg N, et al. (2014) Endothelial markers are associated with thrombosis resistance in acute stroke patients. Eur J Neuroil 21: 643–647.
23. Gauberti M, Martinez de Lazarrondo S, Orset C, Viven G (2014) Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates. J Thromb Haemost 12: 409–414.
24. Roldan V, Marín F, García-Herola A, Lip GYH (2005) Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 116: 321–325.
25. Pinto A, Toutuomo O, Casuccio A, Di Raimondo D, Di Sciacca R, et al. (2009) Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-vascular atrial fibrillation (NVAF). Clin Sci 116: 781–789.
26. Conway DSG, Pearce LA, Chin BSP, Hart RG, Lip GYH (2003) Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107: 3141–3145.
27. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, et al. (1999) Association between variations in coagulation system genes and carotid plaque. Circulation 100: 736–742.
28. Tsoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, et al. (2007) Relative value of inflammatory, hemostatic, and rheological factors for incident
myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 115: 2119–2127.
29. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, et al. (2011) Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 9: 275–281.
30. Lip GY, Blann AD, Farooq IS, Zarifis J, Sagar G, et al. (2002) Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis 13: 339–347.
31. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJJ, et al. (1997) Von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 77: 1104–1108.
32. Claus RA, Bockmeyer CL, Sossdorf M, Lösch W (2010) The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure? Curr Mol Med 10: 236–240.
33. Niewandt B, Kleinschnitz C, Stoll G (2011) Ischaemic stroke: a thrombo-inflammatory disease? J Physiol 589: 4115–4123.
34. Stoll G, Kleinschnitz C, Niewandt B (2010) Combating innate inflammation: a new paradigm for acute treatment of stroke? Ann N Y Acad Sci 1207: 149–154.
35. Soares AL, Kazmi KS, Borges MA, Rosário PW, Fernandes AP, et al. (2011) Elevated plasma factor VIII and von Willebrand factor in women with type 2 diabetes: inflammatory reaction, endothelial perturbation or else? Blood Coagul Fibrinolysis 22: 660–665.
36. Westein E, van der Meer AD, Knijpers MJ, Frimat JP, van den Berg A, et al. (2013) Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner. Proc Natl Acad Sci U S A 110: 1357–1362.
37. Nilsson TK, Spencer JD, Nilsson PM, Elmass S, Jansson JH, et al. (2002) Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma—a 2-year follow-up study. J Cardiovasc Risk 9: 215–221.
38. Jenkins PV, O’Donnell JH (2006) ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 46: 1836–1844.
39. von Beckerath N, Koch W, Mehilli J, Gorchakova O, Braun S, et al. (2004) ABO locus O1 allele and risk of myocardial infarction. Blood Coagul Fibrinolysis 15: 1–6.
40. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69: 1691–1695.
41. Suadicani P, Hein HO, Gyntelberg F (2002) Airborne occupational exposure, ABO phenotype and risk of ischaemic heart disease in the Copenhagen Male Study. J Cardiovasc Risk 9: 191–198.
42. Dmitrieva NI, Burg MB (2014) Secretion of von Willebrand factor by endothelial cells links sodium to hypercoagulability and thrombosis. Proc Natl Acad Sci U S A 111: 6483–6489.